Wyeth Pharmaceuticals LLC

*In association with Wexler Boley & Elgersma LLP, Spector Roseman & Kodroff, P.C., Miller Law LLC, Motley Rice LLC, Quantum Legal LLC, and The Dugan Law Firm, PLC CHICAGO, June 14, 2024 /PRNewswire/ -- Legal Notice Did You Purchase, Pay for, or Provide Reimbursement for Effexor XR® and/or Its Generic Equivalent? You Could Get Money from a Settlement There is a Settlement in a class-action lawsuit with Wyeth (also known as Wyeth LLC and formerly known as Wyeth, Inc. and American Home Products); Wyeth Pharmaceuticals, Inc.; Wyeth-Whitehall Pharmaceuticals; and Wyeth Pharmaceuticals Company (collectively, "Wyeth") and Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively, "Teva"). The lawsuit claims that Wyeth and Teva unlawfully kept generic versions of Effexor XR® off the market, causing consumers and third-party payors to pay more for brand and generic Effexor XR® than they should have. Wyeth and Teva deny they did anything wrong. There has been a settlement with Wyeth; the lawsuit against Teva is ongoing. No one is claiming that Effexor XR® is unsafe. Who is included in the Settlement? You may be included in the Settlement if you are a person or entity that purchased, paid for, and/or reimbursed some or all of the cost of Effexor XR® or AB-rated generic versions of Effexor XR® for yourself, your family, or your members, employees, insureds, participants, or beneficiaries, from June 14, 2008 through May 31, 2011, in the following states: Arizona, California, Florida, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nevada, New Hampshire, New Mexico, New York, North Carolina, Oregon, Rhode Island, South Dakota, Tennessee, West Virginia, and Wisconsin. A more detailed notice, including the full class definition and who is not included, is available at . What does the Settlement provide? Wyeth will pay $25.5 million into a Settlement Fund that will pay (1) money to eligible Class Members; (2) notice and administration costs; (3) service awards to the class representatives who brought the lawsuit; and (4) attorneys' fees, costs, and expenses. How can I get a payment? You must submit a valid claim form to apply for payment from the Settlement Fund. The amount of your payment will depend on the amount of Effexor XR® or AB-rated generic versions of Effexor XR® you purchased and the number of claims that are filed. The Claim Forms, and information on how to submit them, are available at . Claim forms must be postmarked (if mailed) or received (if submitted online) on or before September 16, 2024. What are my rights? Even if you do nothing, you will be bound by the Court's decisions. If you want to keep your right to sue Wyeth yourself, you must exclude yourself by July 29, 2024. If you do not exclude yourself, you may object to the Settlement by July 29, 2024. Detailed instructions about how to act on these rights are available at . The Court will hold a hearing on September 12, 2024 to consider whether to approve the Settlement, a request for attorneys' fees of up to 34% of the Settlement Fund, plus costs and expenses, and service awards to the class representatives. You or your own lawyer may appear and speak at the hearing at your own expense. The Court may change these deadlines or the hearing date and time. Check the website below for updates. Please do not call the Court or the Clerk of the Court for information about the Settlement. For more information: 1-877-933-2882 SOURCE Carella, Byrne, Cecchi, Brody & Agnello, P.C.; Wexler Boley & Elgersma LLP

Sander van Deventer is co-founder and former Chief Technology Officer of the Company Elena Ritsou assumes role of Chief Corporate Officer Barbara Sanders is promoted to Chief Technology Officer Industry veteran Frank Walsh joins as an Independent Board Member AMSTERDAM--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative diseases, today announces the appointment of Sander van Deventer, co-founder and formerly Chief Technology Officer, as Chief Executive Officer. The Company has also made key appointments to its leadership team. Sander van Deventer has 25 years of experience in drug development and a longstanding track record in antibody and gene therapy development. He succeeds Alexander Vos, who led the Company during the start-up phase. “I’m delighted to welcome Sander as our new CEO,” said Carlo Incerti, MD, Chair of the Supervisory Board at VectorY. “We are confident that with his impressive industry track record and scientific knowledge, Sander will lead VectorY forward at this exciting time as we work towards our first IND. I would also like to thank Alexander for his commitment and contribution to VectorY and wish him all the best in his future endeavors.” “In the two years since VectorY’s inception, we have made significant progress in validating our technology and are now advancing towards development,” said Sander van Deventer, Chief Executive Officer of VectorY. “We have a promising technology of vectorized antibodies which has the potential to transform the therapeutic landscape in neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Huntington’s and ultimately dementias. I am looking forward to working with the team to progress our innovative pipeline towards our first IND.” Other VectorY appointments Elena Ritsou joins as Chief Corporate Officer (CCO), a newly created role in which she will lead Business Development and Strategy, Intellectual Property, Legal, Human Resources and Communications. Barbara Sanders is promoted to the position of Chief Technology Officer (CTO), having served as Vice President Vector Development since the Company’s inception. Frank Walsh joins as an Independent Board Member. He brings two decades of experience as a senior executive in pharma and biotech companies as well as invaluable research experience in ALS, where his current work concentrates on the role of the neurotrophin receptor TrkB on motor neuron survival. Sander van Deventer concluded: “We welcome Elena Ritsou as Chief Corporate Officer and Frank Wash as an independent board member and congratulate Barbara Sanders on her new role as Chief Technology Officer. With these valuable additions to the leadership team, VectorY will be in an even stronger position to progress its pioneering work of vectorized antibodies to tackle devastating diseases such as ALS and Huntington’s disease.” -Ends- Notes to Editors Full biographies Sander van Deventer, MD, PhD – Chief Executive Officer Sander is a co-founder of VectorY and has 25 years of experience in drug development. He had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). Sander is also co-founder of Forbion, a leading life science venture capital firm where he is currently an Operating Partner. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT N.V.), currently uniQure N.V. (NASDAQ: QURE), an AAV-based gene therapy company, acting subsequently as CSO, CMO and CEO. He also served as CEO of Dezima. In 2017, he re-joined uniQure as its part-time CSO where he brought the hemophilia B and Huntington’s disease programs to clinical development. Sander is a former professor of Experimental Medicine and Gastroenterology at the Amsterdam Academic Medical Center and of Translational Gastroenterology at the University of Leiden. He authored over 80 book chapters, 600 peer-reviewed papers, organized international scientific conferences, and supervised more than 40 PhD students. He served on the boards of Hookipa, Engene, Borean, Dezima, Argos, and the scientific advisory boards of Hookipa, Argos, Engene and Staten. Elena Ritsou, PhD – Chief Corporate Officer Elena joins VectorY as the Chief Corporate Officer as well as BioGeneration Ventures as a Venture Partner. She brings 20 years of experience in Corporate and Business Development in pharmaceutical and biotech companies, most recently as the Chief Business Officer of Gamma Delta Therapeutics leading its acquisition by Takeda in Q2 2022. Prior to Gamma Delta Elena was Global Head Oncology Business Development at Ipsen Pharma where she was instrumental on late and early-stage transactions and acquisitions. Earlier in her career she held Business Development roles of increasing responsibility at Sanofi and Genzyme. Elena holds a BSc in Immunology from the University of Edinburgh, UK, a PhD in Tumor Immunology from the German Cancer Research Centre, Heidelberg, Germany and a MSc in Finance from HEC Business School, Paris, France. Barbara Sanders, PhD – Chief Technology Officer Barbara is a co-founder of VectorY and has served as Vice President Vector Development since the Company’s inception in 2020. She has over 10 years of experience in viral vector development within large pharmaceutical and biotechnology companies where she led multiple discovery and CMC teams of ~25 FTEs. Thanks to her contribution several viral vectored vaccines were successfully designed and developed, including a commercialized Ebola vaccine (Zabdeno) and others which are currently in clinical development for polio, zika, HIV and RSV. Barbara completed a PhD in molecular virology at the University of Amsterdam and is an inventor of eight patents. Frank S Walsh, PhD – Independent Board Member Frank is an accomplished pharmaceutical and biotechnology senior executive with over 20 years of experience. He currently serves as the founding CEO of Ossianix. Frank has had a long-term research interest in ALS, where his work initially focused on developing human neuronal cell culture models and on the role of autoimmunity. His current work is determining the role of the neurotrophin receptor TrkB on motor neuron survival. As head of Discovery Research worldwide at Wyeth Pharmaceuticals in Collegeville, PA he studied myostatin and neutralizing antibodies in the SOD-1 ALS mouse model. Prior to joining Wyeth, he was SVP at GlaxoSmithKline UK and Head of the Neurology CEDD and VP of Neuroscience Research at Smith Kline Beecham UK. Before joining the pharmaceutical industry, Frank had a distinguished academic career in Neuroscience as the Sir William Dunn Professor of Experimental Pathology at London’s UMDS, Guy’s Hospital. Frank has served on the research committee of the Motor Neuron Disease Association in the UK and was Chairman of the ALSA Ice Bucket Challenge drug discovery initiative. Currently, he is a member of the Scientific Advisory Board at Target ALS, New York and the Packard Center, Johns Hopkins University, Baltimore. He received his PhD from University College London and has authored over 200 scientific publications. He is a Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences and has honorary degrees from the University of Perugia and Bologna, Italy and Dundee and Strathclyde, UK. About VectorY VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative diseases with high unmet medical need such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease. VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative diseases, VectorY's synergistic technologies may be applied across a wide range of indications. VectorY was founded in October 2020 and is based on the Amsterdam Science Park. For more information, see . View source version on businesswire.com: Contacts VectorY Therapeutics B.V. Sariette Witte, Head of Communications E-mail: sariette.witte@vectorytx.com Tel: +31 681 174 072 Instinctif Partners (media enquiries) Melanie Toyne-Sewell / Giulia Lasagni / Manisha Kuttetira E-mail: VectorY@instinctif.com Tel: +44 20 7457 2020 Source: VectorY View this news release online at:

A biotech’s first drug approval is a process often years in the making and a crowning achievement for founder-CEOs who have run the race from the beginning. After 17 years watching Cara Therapeutics grow to a commercial brand, this biotech’s founding CEO is now ready to move on to his next phase. Cara has appointed Christopher Posner, a current board member and former CEO of Leo Pharma’s US branch, as its next leader, replacing founding CEO Derek Chalmers, the company said Wednesday. Chalmers will move over into a senior advisory role, with Posner set to take on the mantle Nov. 9. Chalmers founded Cara way back in 2004 and has served as CEO ever since, watching the biotech cross the FDA finish line for the first time in August with Korsuva (difelikefalin), a novel kappa opioid receptor agonist injection to treat severe-to-moderate pruritus, or itching, in patients with chronic kidney disease undergoing dialysis. Prior to Cara, Chalmers co-founded Arena Pharmaceuticals and served as its VP and executive director from June 1997 until May 2004. Previously, he was a group leader at Neurocrine Biosciences. Chalmers had this to say about his departure: Meanwhile, Posner most recently served as president and CEO of Leo Pharma, the US affiliate of Leo Pharma A/S, and previously was head of worldwide commercial operations at R-Pharma-US, a specialty pharma in the oncology and chronic immune disorder space. Before that, Posner held senior management roles in commercial and marketing operations at Bristol-Myers Squibb, Pfizer, Wyeth Pharmaceuticals and Endo. Posner will take the helm as Cara and partner Vifor Pharma prep a Q1 launch for Korsuva. As part of the partners’ commercialization agreement in the US, Cara and Vifor will split profits 60-40 in dialysis clinics not owned by Fresenius Medical Care, the clinical care arm of the larger Vifor Fresenius Medical Care Renal Pharma business. Meanwhile, in Fresenius clinics, the companies will split profits 50-50. In a conversation with Endpoints News in April 2020, Chalmers indicated Fresenius clinics represented around 38% of the market. The agency based its review on two Phase III trials, KALM-1 and KALM-2, with the latter study showing 54% of patients dosed with Korsuva posted a 3-point or greater improvement from baseline in the weekly mean of the 24-hour Worst Itch Intensity Numeric Rating Scale (WI-NRS) score compared with 42% on placebo. The drug’s data package included results from an additional 32 trials.